{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim Y"],"funding":["Pfizer","Pfizer (Pfizer Inc.)"],"pagination":["59"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11255222"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["Hot flashes (HF) are a common adverse event of prolonged tamoxifen use in women with estrogen receptor-positive breast cancer, impacting psychiatric health and quality of life. While desvenlafaxine does not interact with tamoxifen, its efficacy and safety in breast cancer patients remain unstudied. This phase 3, four-week, multi-center, three-arm, parallel-group, randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of desvenlafaxine for treating HF in women with breast cancer taking tamoxifen, assessing potential differential effects in patients with psychiatric and inflammatory conditions. Between December 2017 and February 2019, 57 women aged 19 or older, regularly taking tamoxifen as adjuvant therapy, experiencing moderate-to-severe HFs for more than a"],"journal":["NPJ breast cancer"],"pubmed_title":["Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial."],"pmcid":["PMC11255222"],"funding_grant_id":["53232755"],"pubmed_authors":["Kim TY","Lee HB","Kim H","Moon HG","Han W","Kim M","Spiegel D","Yeom CW","Lee KM","Hahm BJ","Kim Y","Kim JH","Lee HJ","Im SA","Lee KH","Son KL"],"additional_accession":[]},"is_claimable":false,"name":"Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial.","description":"Hot flashes (HF) are a common adverse event of prolonged tamoxifen use in women with estrogen receptor-positive breast cancer, impacting psychiatric health and quality of life. While desvenlafaxine does not interact with tamoxifen, its efficacy and safety in breast cancer patients remain unstudied. This phase 3, four-week, multi-center, three-arm, parallel-group, randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of desvenlafaxine for treating HF in women with breast cancer taking tamoxifen, assessing potential differential effects in patients with psychiatric and inflammatory conditions. Between December 2017 and February 2019, 57 women aged 19 or older, regularly taking tamoxifen as adjuvant therapy, experiencing moderate-to-severe HFs for more than a","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-02T22:54:50.639Z","creation":"2025-04-06T17:11:10.159Z"},"accession":"S-EPMC11255222","cross_references":{"pubmed":["39019875"],"doi":["10.1038/s41523-024-00668-w"]}}